For a substantial proportion of patients with deep venous thrombosis (DVT), current treatment strategies are suboptimal and new treatment options are needed. Especially for the group of patients who are at the highest risk for post-thrombotic syndrome, new treatment modalities such as catheter-directed thrombolysis and additional stenting are being investigated. With current clinical studies addressing new technical options, the medical management of patients following these interventions deserves attention. The duration of anticoagulant treatment following surgical or radiological interventions for DVT seems not to be influenced by the presence of a venous stent. According to recent ACCP 2012 guidelines the anticoagulant management in patients who have had any method of thrombus removal performed, the same intensity and duration of anticoagulant therapy as in comparable patients who do not undergo thrombosis removal is recommended (Grade 1B). In the acute phase of thrombosis, irrespective of the technique and whether or not stenting is applied, immediate anticoagulation following the procedure is pertinent to reduce the risk of recurrent thrombosis and thrombus propagation. The long-term treatment duration after venous interventions therefore may be tailored based on common risk factors for recurrent thrombosis and the individual risk for bleeding. Selected thrombophilia factors, d-dimer assessment and residual venous thrombosis provide markers for recurrent DVT. Currently, vitamin K antagonists) provide the main anticoagulants for (prolonged) anticoagulation, while the new oral anticoagulants emerge as promising alternatives. In case prolonged anticoagulation after unprovoked DVT is not indicated, cardiovascular risk management is warranted because of an increased rate of arterial thrombotic events after DVT; aspirin may be indicated as secondary prevention against recurrent thrombosis (while providing primary prevention against arterial thrombosis).
Get full access to this article
View all access options for this article.
References
1.
KearonS. Dabigatran versus warfarin in the treatment of acute venous thromboembolism.New Engl J Med2009; 361: 2342–52
2.
PrandoniP, LensingAW, PrinsMH. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial.Ann Intern Med2004; 141: 249–56
3.
BrandjesDP, BüllerHR, HeijboerH. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis.Lancet1997; 349: 759–62
4.
PrandoniP, LensingAWA, CogoA. The long-term clinical course of acute deep vein thrombosis.Ann Intern Med1996; 125: 1–7
5.
EndenT, HaigY, KlowNE. CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomized controlled trial.Lancet2012; 379: 31–8
6.
KearonC, AklEA, ComerotaAJ. American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest2012; 141 (Suppl.): e419S–94S
7.
ten Cate-HoekAJ, PrinsMH. Appropriate level and length of postthrombotic warfarin treatment: an evaluation of recent developments.Curr Opin Hematol2004; 11: 182–6. Review
8.
BaglinT, LuddingtonR, BrownK, BaglinC. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study.Lancet2003; 362: 523–6
9.
KearonC. Duration of therapy for acute venous thromboembolism.Clin Chest Med2003; 24: 63–72
10.
de JongPG, CoppensM, MiddeldorpS. Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term.Br J Haematol2012; 158: 433–41
11.
LijferingWM, CoppensM, VeegerNJ. Hyperhomocysteinemia is not a risk factor for venous and arterial thrombosis, and is associated with elevated factor VIII levels.Thromb Res2008; 123: 244–50
12.
JenkinsPV, RawleyO, SmithOP, O’DonnellJS. Elevated factor VIII levels and risk of venous thrombosis.Br J Haematol2012; 157: 653–63. Review
13.
LijferingWM, MulderR, ten KateMK, VeegerNJ, MulderAB, van der MeerJ. Clinical relevance of decreased free protein S levels: results from a retrospective family cohort study involving 1143 relatives.Blood2009; 113: 1225–30
14.
Farmer-BoatwrightMK, RoubeyRA. Venous thrombosis in the antiphospholipid syndrome.Arterioscler Thromb Vasc Biol2009; 29: 321–5. Review
15.
LeeAY, LevineMN, BakerRI. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.N Engl J Med2003; 349: 146–53
16.
StrijkersRH, ten Cate-HoekAJ, GrommesJ, ArnoldussenC, WittensCH. Catheter-directed thrombolysis in iliofemoral deep-vein thrombosis.Ned Tijdschr Geneeskd2012; 156: A4759. Review
17.
KahnSR, GinsbergJS. Relationship between deep venous thrombosis and the postthrombotic syndrome.Arch Intern Med2004; 164: 17–26
18.
HeitJA, RookeTW, SilversteinMD. Trends in the incidence of venous stasis syndrome and venous ulcer: a 25-year population-based study.J Vasc Surg2001; 33: 1022–7
19.
KahnSR, ShrierI, JulianJA. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis.Ann Intern Med2008; 149: 698–707
20.
GilRJ, PerezAM, AriasJB, PascualFB, RomeroES. Agenesis of the inferior vena cava associated with lower extremities and pelvic venous thrombosis.J Vasc Surg2006; 44: 1114–6
21.
KwakH-S, HanY-M, LeeY-S, JinG-Y, ChungG-H. Stents in common iliac vein obstruction with acute ipsilateral deep venous thrombosis: early and late results.J Vasc Interv Radiol2005; 16: 815–22
22.
Ten Cate-HoekAJ, PrinsMH. Management studies using a combination of D-dimer test result and clinical probability to rule out venous thromboembolism: a systematic review.J Thromb Haemost2005; 3: 2465–70
23.
PalaretiG, LegnaniC, CosmiB, GuazzalocaG, PancaniC, CoccheriS. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.Thromb Haemost2002; 87: 7–12
24.
TripodiA. D-dimer testing in laboratory practice.Clin Chem2011; 57: 1256–62. Review
25.
VerhovsekM, DouketisJD, YiQ. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism.Ann Intern Med2008; 149: 481–90, W94. Review
26.
BoumanAC, SmitsJJ, Ten CateH, Ten Cate-HoekAJ. Markers of coagulation, fibrinolysis and inflammation in relation to post-thrombotic syndrome.J Thromb Haemost2012; 10: 1532–8
27.
LatellaJ, DesmaraisS, MironMJ. Relation between D-dimer level, venous valvular reflux and the development of post-thrombotic syndrome after deep vein thrombosis.J Thromb Haemost2010; 8: 2169–75
28.
MazettoBM, OrsiFL, BarnabeA, De PaulaEV, Flores-NascimentoMC, Annichino-BizzacchiJM. Increased ADAMTS13 activity in patients with venous thromboembolism.Thromb Res2012; 130: 889–93
29.
StainM, SchonauerV, MinarE. The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease.J Thromb Haemost2005; 3: 2671–6
30.
CosmiB, LegnaniC, TosettoA. PROLONG Investigators; FCSA, Italian Federation of Anticoagulation Clinics. Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study.Thromb Haemost2010; 103: 1152–60
31.
SiragusaS, MalatoA, SacculloG. Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study.Am J Hematol2011; 86: 914–7
32.
SiragusaS, MalatoA, AnastasioR. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression Ultrasonography (DACUS) study.Blood2008; 112: 511–5
33.
Le GalG, CarrierM, KovacsMJ. Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study.J Thromb Haemost2011; 9: 1126–32
34.
CarrierM, RodgerMA, WellsPS, RighiniM, LE GalG. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis.J Thromb Haemost2011; 9: 1119–25
35.
TanM, MosIC, KlokFA, HuismanMV. Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: a sytematic review.Br J Haematol2011; 153: 168–78
36.
DouketisJ, TosettoA, MarcucciM. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.Ann Intern Med2010; 153: 523–31
37.
KoskinasKC, ChatzizisisYS, AntoniadisAP, GiannoglouGD. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation.J Am Coll Cardiol2012; 59: 1337–49. Review
38.
KleinegrisMC, Ten Cate-HoekAJ, Ten CateH. Coagulation and the vessel wall in thrombosis and atherosclerosis.Pol Arch Med Wewn2012; 122: 557–66
